Literature DB >> 15977969

Acellular pertussis vaccine safety and efficacy in children, adolescents and adults.

Janet R Casey1, Michael E Pichichero.   

Abstract

This review offers a perspective on the acellular pertussis vaccine efficiency trials concluded in the 1990s and presents the main conclusions of a meta-analysis of 52 studies that assessed the safety and efficacy of the diphtheria-tetanus (DT)-whole cell pertussis (DTwP) and DT-acellular pertussis (DTaP) vaccines administered to children. A clear serological correlate of immunity to pertussis following DTaP vaccination was not identified despite an intensive analysis. It can be speculated that this may be because various combinations of antibody to agglutinogens (pertussis toxin, filamentous haemagglutinin, pertactin and fimbriae) provide protection, or because serum antibody levels and responses do not uniformly reflect mucosal IgA antibody levels.Long-term efficacy following DTaP vaccination is becoming characterised and cell-mediated immunity (T-cell memory) may have importance. DTaP vaccination appears to establish herd immunity after sufficient uptake within communities and countries. As experience with DTaP vaccine safety has accumulated, a 1-2% occurrence of large, local injection reactions with all products has been defined for booster doses. The pathophysiological mechanisms for the reactions are not established but a majority appear likely to be IgE-mediated reactive oedema and a minority to be IgG-mediated reactive Arthus-type reactions. DTwP and DTaP combinations with other vaccines have been studied and licensed; the most controversial combination products are the DTaP/Haemophilus influenzae type B polysaccharide conjugate vaccines. Pertussis epidemiology is changing with a clear increase in occurrence in adolescents and adults. This development has spurred studies and licensure of safer DTaP vaccines for this older population. The economic impact of pertussis and transmission from adults to vulnerable infants provides a cost-benefit justification for widespread use of DTaP vaccines in all age groups with routine boosting every 10 years.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15977969     DOI: 10.2165/00003495-200565100-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  152 in total

1.  An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates.

Authors:  E P Rothstein; E L Anderson; M D Decker; G A Poland; K S Reisinger; M M Blatter; R M Jacobson; C A Mink; D Gennevois; A E Izu; F Sinangil; A G Langenberg
Journal:  Vaccine       Date:  1999-08-06       Impact factor: 3.641

2.  Recommended childhood and adolescent immunization schedule--United States, 2003.

Authors: 
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

3.  Comparison of antibody titers in eleven- to twelve-year old Japanese school children six years after administration of acellular and whole cell pertussis vaccines combined with diphtheria-tetanus toxoids.

Authors:  K Okada; K Ueda; K Morokuma; J Fukushige; C Miyazaki
Journal:  Pediatr Infect Dis J       Date:  1998-12       Impact factor: 2.129

4.  The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination.

Authors:  D Goldblatt; P Richmond; E Millard; C Thornton; E Miller
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

5.  Return of epidemic pertussis in the United States.

Authors:  J W Bass; R R Wittler
Journal:  Pediatr Infect Dis J       Date:  1994-05       Impact factor: 2.129

Review 6.  Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration.

Authors:  M Campins-Martí; H K Cheng; K Forsyth; N Guiso; S Halperin; L M Huang; J Mertsola; G Oselka; J Ward; C H Wirsing von König; F Zepp
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

7.  Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP--T-HBs) administered at 2, 4, 6 and 12-14 months of age.

Authors:  J G Liese; S Stojanov; F Berut; P Minini; E Harzer; S Jow; F Schödel; J Boslego; A Hoffenbach; A Kronwitter; B H Belohradsky
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

8.  Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants.

Authors:  M Blennow; M Granström
Journal:  Pediatrics       Date:  1989-07       Impact factor: 7.124

9.  Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria, tetanus, acellular pertussis and hepatitis B (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine, to infants at 2, 4 and 6 months of age.

Authors:  J Arístegui; R Dal-Ré; E Garrote; A González; J P Arrate; A Pérez
Journal:  Vaccine       Date:  1998-12       Impact factor: 3.641

10.  Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants.

Authors:  N Watemberg; R Dagan; Y Arbelli; I Belmaker; A Morag; L Hessel; B Fritzell; A Bajard; L Peyron
Journal:  Pediatr Infect Dis J       Date:  1991-10       Impact factor: 2.129

View more
  6 in total

1.  Update on available vaccines in India: report of the APPA VU 2010: I.

Authors:  Sunil Karande
Journal:  Indian J Pediatr       Date:  2011-03-05       Impact factor: 1.967

2.  Nonprotective responses to pediatric vaccines occur in children who are otitis prone.

Authors:  Michael E Pichichero; Janet R Casey; Anthony Almudevar
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 3.  Challenges in vaccination of neonates, infants and young children.

Authors:  Michael E Pichichero
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

4.  Modelling the impact of extended vaccination strategies on the epidemiology of pertussis.

Authors:  M H Rozenbaum; R De Vries; H H LE; M J Postma
Journal:  Epidemiol Infect       Date:  2011-11-24       Impact factor: 2.451

5.  Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model.

Authors:  Robin de Vries; Mirjam Kretzschmar; Joop F P Schellekens; Florens G A Versteegh; Tjalke A Westra; John J Roord; Maarten J Postma
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

6.  Safety of pertussis vaccination in pregnant women in UK: observational study.

Authors:  Katherine Donegan; Bridget King; Phil Bryan
Journal:  BMJ       Date:  2014-07-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.